Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Ramanathan

Showing results (131-140 of 302) with videos related to

Pageof 31
Sort By:
Clinical Colorectal Cancer|May 27, 2008
A four-arm, randomized, multicenter phase II trial of oxaliplatin combined with varying schedules of 5-fluorouracil as first-line therapy in previously untreated advanced colorectal cancerRamesh K Ramanathan, Georg A Bjarnason, Stephen Alan Bernard, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|August 5, 2017
<sup>18</sup>F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancerRonald L Korn, Daniel D Von Hoff, Mitesh J Borad, et al.
Investigational New Drugs|March 10, 2006
Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapyHitendra Patel, Ronald Stoller, Miklos Auber, et al.
Clinical Colorectal Cancer|December 17, 2005
Phase I/II dose-escalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancerHoward Hochster, Erika Kettner, Hendrik Kroning, et al.
Frontiers in Pharmacology|February 2, 2013
Clonal evolution and therapeutic resistance in solid tumorsMichael T Barrett, Elizabeth Lenkiewicz, Lisa Evers, et al.
Investigational New Drugs|March 23, 2011
A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancerA B El-Khoueiry, R K Ramanathan, D Y Yang, et al.
American Journal of Clinical Oncology|March 24, 2012
Phase I trial of AEG35156 an antisense oligonucleotide to XIAP plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinomaDaruka Mahadevan, Pavani Chalasani, Diane Rensvold, et al.
BMC Cancer|October 27, 2012
PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumoursMark J McKeage, Michael B Jameson, Ramesh K Ramanathan, et al.
The American Journal of Cardiology|April 4, 1998
Abnormal coronary flow in infarct arteries 1 year after myocardial infarction is predicted at 4 weeks by corrected Thrombolysis in Myocardial Infarction (TIMI) frame count and stenosis severityJ K French, C J Ellis, B J Webber, et al.
Letters in Applied Microbiology|May 7, 2025
Unveiling the virulence, genetic links, and enzyme profiles of bivalve-associated Vibrio parahaemolyticus from the southwest coast of IndiaRemya Bhaskaran, Krupesha Sharma Sulumane Ramachandra, Reynold Peter, et al.
Pageof 31

Showing results (131-140 of 302) with videos related to

Sort By:
Pageof 31
Clinical Colorectal Cancer|May 27, 2008
A four-arm, randomized, multicenter phase II trial of oxaliplatin combined with varying schedules of 5-fluorouracil as first-line therapy in previously untreated advanced colorectal cancerRamesh K Ramanathan, Georg A Bjarnason, Stephen Alan Bernard, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|August 5, 2017
<sup>18</sup>F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancerRonald L Korn, Daniel D Von Hoff, Mitesh J Borad, et al.
Investigational New Drugs|March 10, 2006
Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapyHitendra Patel, Ronald Stoller, Miklos Auber, et al.
Clinical Colorectal Cancer|December 17, 2005
Phase I/II dose-escalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancerHoward Hochster, Erika Kettner, Hendrik Kroning, et al.
Frontiers in Pharmacology|February 2, 2013
Clonal evolution and therapeutic resistance in solid tumorsMichael T Barrett, Elizabeth Lenkiewicz, Lisa Evers, et al.
Investigational New Drugs|March 23, 2011
A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancerA B El-Khoueiry, R K Ramanathan, D Y Yang, et al.
American Journal of Clinical Oncology|March 24, 2012
Phase I trial of AEG35156 an antisense oligonucleotide to XIAP plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinomaDaruka Mahadevan, Pavani Chalasani, Diane Rensvold, et al.
BMC Cancer|October 27, 2012
PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumoursMark J McKeage, Michael B Jameson, Ramesh K Ramanathan, et al.
The American Journal of Cardiology|April 4, 1998
Abnormal coronary flow in infarct arteries 1 year after myocardial infarction is predicted at 4 weeks by corrected Thrombolysis in Myocardial Infarction (TIMI) frame count and stenosis severityJ K French, C J Ellis, B J Webber, et al.
Letters in Applied Microbiology|May 7, 2025
Unveiling the virulence, genetic links, and enzyme profiles of bivalve-associated Vibrio parahaemolyticus from the southwest coast of IndiaRemya Bhaskaran, Krupesha Sharma Sulumane Ramachandra, Reynold Peter, et al.
Pageof 31